Preclinical Study Identifies Spyryx’s SPX-101 as Potential Treatment for Mucus Clearance in CF Patients
Mutated mice that inhaled SPX-101 lived longer, according to a new preclinical study that highlights the drug’s potential to clear mucus and hydrate airways in patients with cystic fibrosis (CF). The study, “SPX-101 is a Novel ENaC-targeted Therapeutic for Cystic Fibrosis that Restores Mucus Transport,” appeared in the American Journal of…